High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment

Molecular Therapy

Volumn 17, Issue 6, 2009, Pages 1003-1011

  Balani, Poonam ^a   Boulaire, Jerome ^a   Zhao, Ying ^a,b   Zeng, Jieming ^a   Lin, Jiakai ^a   Wang, Shu ^a,b  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BACULOVIRUS VECTOR; GANCICLOVIR; HERPES SIMPLEX VIRUS THYMIDINE KINASE; HIGH MOBILITY GROUP B2 PROTEIN; SURVIVIN; THYMIDINE KINASE; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN LEVEL; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PROMOTER REGION; SUICIDE GENE THERAPY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; XENOGRAFT;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GANCICLOVIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GLIOBLASTOMA; HELA CELLS; HMGB2 PROTEIN; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; SIMPLEXVIRUS;

EID: 67349115991     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.22     Document Type: Article

References (47)

1. Pulkkanen, KJ and Yla-Herttuala, S (2005). Gene therapy for malignant glioma: Current clinical status. Mol Ther 12: 585-598.
2. Harrington, KJ, Linardakis, E and Vile, RG (2000). Transcriptional control: An essential component of cancer gene therapy strategies? Adv Drug Deliv Rev 44: 167-184.
3. Robson, T and Hirst, DG (2003). Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003: 110-137.
4. King, GD, Curtin, JF, Candolfi, M, Kroeger, K, Lowenstein, PR and Castro, MG (2005). Gene therapy and targeted toxins for glioma. Curr Gene Ther 5: 535-557.
5. Sadeghi, H and Hitt, MM (2005). Transcriptionally targeted adenovirus vectors. Curr Gene Ther 5: 411-427.
6. Chen, MH, Yang, WK, Whang-Peng, J, Lee, LS and Huang, TS (1998). Differential inducibilities of GFAP expression, cytostasis and apoptosis in primary cultures of human astrocytic tumours. Apoptosis 3 171-182.
7. McKie, EA, Graham, DI and Brown, SM (1998). Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector - potential glioblastoma targeting. Gene Ther 5: 440-450.
8. Vandier, D, Rixe, O, Brenner, M, Gouyette, A and Besnard, F (1998). Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res 58: 4577-4580.
9. Zamorano, A, Mellstrom, B, Vergara, P, Naranjo, JR and Segovia, J (2004). Glial-specific retrovirally mediated gas1 gene expression induces glioma cell apoptosis and inhibits tumor growth in vivo. Neurobiol Dis 15: 483-491.
10. Wang, CY, Li, F, Yang, Y, Guo, HY, Wu, CX and Wang, S (2006). Recombinant baculovirus containing the diphtheria toxin A gene for malignant glioma therapy. Cancer Res 66: 5798-5806.
11. Horst, M, Brouwer, E, Verwijnen, S, Rodijk, M, de Jong, M, Hoeben, R et al. (2007). Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus. J Gene Med 9: 1071-1079.
12. Bush, TG, Savidge, TC, Freeman, TC, Cox, HJ, Campbell, EA, Mucke, L et al. (1998). Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 93: 189-201.
13. Delaney, CL, Brenner, M and Messing, A (1996). Conditional ablation of cerebellar astrocytes in postnatal transgenic mice. J Neurosci 16: 6908-6918.
14. Bush, TG, Puvanachandra, N, Horner, CH, Polito, A, Ostenfeld, T, Svendsen, CN et al. (1999). Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23: 297-308.
15. Faulkner, JR, Herrmann, JE, Woo, MJ, Tansey, KE, Doan, NB and Sofroniew, MV (2004). Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24: 2143-2155.
16. Rhodes, DR, Yu, J, Shanker, K, Deshpande, N, Varambally, R, Ghosh, D et al. (2004). Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101: 9309-9314.
17. Ronfani, L, Ferraguti, M, Croci, L, Ovitt, CE, Scholer, HR, Consalez, GG et al. (2001). Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein Hmgb2. Development 128: 1265-1273.
18. Barrett, T, Suzek, TO, Troup, DB, Wilhite, SE, Ngau, WC, Ledoux, P et al. (2005). NCBI GEO: Mining millions of expression profiles-database and tools. Nucleic Acids Res 33: D562-D566.
19. Fukuda, S and Pelus, LM (2006). Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5: 1087-1098.
20. Alavi, JB and Eck, SL (2001). Gene therapy for high grade gliomas. Expert Opin Biol Ther 1: 239-252.
21. Sarkis, C, Serguera, C, Petres, S, Buchet, D, Ridet, JL, Edelman, L et al. (2000). Efficient transduction of neural cells in vitro and in vivo by a baculovirus-derived vector. Proc Natl Acad Sci USA 97: 14638-14643.
22. Lehtolainen, P, Tyynela, K, Kannasto, J, Airenne, KJ and Yla-Herttuala, S (2002). Baculoviruses exhibit restricted cell type specificity in rat brain: A comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo. Gene Ther 9: 1693-1699.
23. Li, Y, Wang, X, Guo, H and Wang, S (2004). Axonal transport of recombinant baculovirus vectors. Mol Ther 10: 1121-1129.
24. Wang, CY and Wang, S (2006). Astrocytic expression of transgene in the rat brain mediated by baculovirus vectors containing an astrocyte-specific promoter. Gene Ther 13: 1447-1456.
25. Thomas, JO (2001). HMG1 and 2: Architectural DNA-binding proteins. Biochem Soc Trans 29: 395-401.
26. Koon, N, Schneider-Stock, R, Sarlomo-Rikala, M, Lasota, J, Smolkin, M, Petroni, G et al. (2004). Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53: 235-240.
27. Varma, RR, Hector, SM, Clark, K, Greco, WR, Hawthorn, L and Pendyala, L (2005). Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 14: 925-932.
28. Xing, Z, Conway, EM, Kang, C and Winoto, A (2004). Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 199: 69-80.
29. Xie, D, Zeng, YX, Wang, HJ, Wen, JM, Tao, Y, Sham, JS et al. (2006). Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 94: 108-114.
30. Van Houdt, WJ, Haviv, YS, Lu, B, Wang, M, Rivera, AA, Ulasov, IV et al. (2006). The human survivin promoter: A novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 104: 583-592.
31. Ulasov, IV, Zhu, ZB, Tyler, MA, Han, Y, Rivera, AA, Khramtsov, A et al. (2007). Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 18: 589-602.
32. Zhu, ZB, Makhija, SK, Lu, B, Wang, M, Rivera, AA, Kim-Park, S et al (2005). Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. Int J Oncol 27: 237-246.
33. Sasaki, T, Lopes, MB, Hankins, GR and Helm, GA (2002). Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol 104: 105-109.
34. Pennartz, S, Belvindrah, R, Tomiuk, S, Zimmer, C, Hofmann, K, Conradt, M et al. (2004). Purification of neuronal precursors from the adult mouse brain: Comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis. Mol Cell Neurosci 25: 692-706.
35. Jiang, Y, de Bruin, A, Caldas, H, Fangusaro, J, Hayes, J, Conway, EM et al. (2005). Essential role for survivin in early brain development. J Neurosci 25: 6962-6970.
36. Ulasov, IV, Rivera, AA, Sonabend, AM, Rivera, LB, Wang, M, Zhu, ZB et al. (2007). Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther 6: 679-685.
37. Herraiz, M, Beraza, N, Solano, A, Sangro, B, Montoya, J, Qian, C et al. (2003). Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. Hum Gene Ther 14 463-472.
38. van der Eb, MM, Geutskens, SB, van Kuilenburg, AB, van Lenthe, H, van Dierendonck, JH, Kuppen, PJ et al. (2003). Ganciclovir nucleotides accumulate in mitochondria of rat liver cells expressing the herpes simplex virus thymidine kinase gene. J Gene Med 5: 1018-1027.
39. Brand, K, Arnold, W, Bartels, T, Lieber, A, Kay, MA, Strauss, M et al (1997). Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther 4: 9-16.
40. van der Eb, MM, Cramer, SJ, Vergouwe, Y, Schagen, FH, van Krieken, JH, van der Eb, AJ et al. (1998). Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther 5: 451-458.
41. Thust, R, Tomicic, M, Klocking, R, Wutzler, P and Kaina, B (2000). Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: Comparison of ganciclovir, penciclovir and aciclovir. Mutagenesis 15: 177-184.
42. Zhang, Y, Huang, SZ, Wang, S and Zeng, YT (2005). Development of an HSV-tk transgenic mouse model for study of liver damage. FEBS J 272: 2207-2215.
43. Wallace, H, Clarke, AR, Harrison, DJ, Hooper, ML and Bishop, JO (1996). Ganciclovir-induced ablation non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis. Oncogene 13: 55-61.
44. Muller, S, Ronfani, L and Bianchi, ME (2004). Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255: 332-343.
45. Zeng, J, Du, J, Zhao, Y, Palanisamy, N and Wang, S (2007). Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells. Stem Cells 25: 1055-1061.
46. Reubinoff, BE, Itsykson, P, Turetsky, T, Pera, MF, Reinhartz, E, Itzik, A et al. (2001). Neural progenitors from human embryonic stem cells. Nat Biotechnol 19: 1134-1140.
47. Livak, KJ and Schmittgen, TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.